期刊文献+

单克隆抗体Denosumab治疗乳腺癌的研究进展 被引量:1

Progress of the monoclonal antibody denosumab in breast cancer therapy
原文传递
导出
摘要 目的:总结Denosumab在乳腺癌相关治疗领域的应用研究进展。方法:应用PUBMED和CNKI期刊全文数据库检索系统,以"Denosumab,RANKL,乳腺肿瘤,骨质疏松,骨转移癌"等为关键词,检索2004-2010的相关文献.共检索到英文文献117篇,中文文献2篇,通过查找全文,排除重复研究及与本研究无关的文献,符合条件的21篇文献纳入分析。结果:单克隆抗体Denosumab靶向细胞核因子κB受体活化因子配基(receptor activator of nuclear factor-κB ligand,RANKL),可以特异性地阻断破骨细胞生成及存活,在治疗骨质疏松症及代谢性骨病中表现良好。近年关于Denosumab在乳腺癌治疗领域中的初步研究显示,Denosumab对于改善骨密度及骨质代谢标志等方面,有快速、特异和持久的治疗作用;且未发生治疗相关的严重不良反应。结论:Denosumab对乳腺癌引发骨质破坏确有一定作用,但其长期随访结果以及与常规乳腺癌治疗手段的联合应用价值,仍有待进一步研究。 OBJECTIVE: To summarize the advance of Deno- sumab research in breast cancer treatment. METHODS: By PubMed and CNKI retrieval system, with Denosumab, breast neoplasms, osteoporosis, osseous metastases'as the key words, a total of 117 papers of literatures in English and 2 in Chinese were retrieved from 2004 to 2010. The articles that were repetitive studies and had no relations with the study were excluded, and 21 articles were included in reference study finally. RESULTS: Receptor activator of nuclear factor-kB ligand(RANKL) is found to be an essential mediator of osteoclast differentiation, fun-ction, and survival. The monoelonal antibody Denosumab binds and neutralizes RANKL. Some papers have evaluated the efficacy and safety of De- nosumab in patients with osteo-porosis. Denosumab also is found to inhibit bone mineral resorption and increase bone density in the treatment of bone destruction and bone metastases caused by breast cancer, including reductions in markers of bone turnover, with no relevant severe adverse events. CONCLUSIONS: Denosumab have primarily been documented efficacy and safety as a potential treat- ment for bone destruction associated with breast cancer. Additional clinical trial is needed to completely establish the long-term follow- up survey,and the combination of Denosumab and the current ther- apies of breast cancer.
出处 《中华肿瘤防治杂志》 CAS 2011年第1期78-80,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤 抗体 单克隆 综述文献 breast neoplasms antibodies, monoclonal review literature
  • 引文网络
  • 相关文献

参考文献5

  • 1Van Poznak C. Managing bone mineral density with oral bisphospho-nate therapy in women with breast cancer receiving adjuvant aro-matase inhibition[J]. Breast Cancer Res, 2010, 12(3) :110.
  • 2Reid D M, Doughty J, Eastell R, et al. Guidance for the man-agement of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group[J]. CancerTreat Rev, 2008, 34(Suppl 1) :3-18.
  • 3Kendler D L, Roux C, Benhamou C L, et al. Effects of deno- sumab on bone mineral density and bone turnover in postmeno- pausal women transitioning from alendronate therapy[J]. J Bone Miner Res, 2010,25(1) :72-81.
  • 4Coleman R E. Effect of anastrozole on bone mineral density: 5-year results from the ' Arimidex' , Tamoxifen, Alone or in Combination (ATAC) trial[J]. J Clin Oneol, 2006,24(5 SuppI): 511.
  • 5Neville-Webbe H L, Coleman R E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease[J]. Eur J Cancer, 2010, 46(7) : 1211-1222.

同被引文献10

  • 1Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibi- tor letrozole as sole therapy[Jl. Br J Cancer, 2011,105 (12) :1825-1829.
  • 2Cohen M H, Johnson J R, Li N, et al. Approval summa- ry: letrozole in the treatment of postmenopausal women with advanced breast cancer[ J]. Clin Cancer Res, 2002,8 ( 3 ) : 665-669.
  • 3Higgins J P T, Green S. Cochrane handbook for systemat- ic reviews of interventions [ M/OLI. Version 5.0.2. [ S. 1. ] : The Cochrane Collaboration, 2009. Available at: www. cochrane-handbook, org.
  • 4Abo-Touk N A, Sakr H A, Abd E1-Lattef A. Switching to letrozole versus continued tamoxifen therapy in treatment of postmenopausal women with early breast cancer [ J ]. J Egypt Natl Canc Inst, 2010,22( 1 ) :79-85.
  • 5Irish W, Sherrill B, Cole B, et al. Quality-adjusted sur- vlval in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer [ J ]. Ann Oncol, 2005,16(9) :1458-1462.
  • 6Mann B S, Johnson J R, Kelly R, et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen[ J]. Clin Cancer Res, 2005,11 (16) :5671-5677.
  • 7Regan M M, Neven P, Giobbie-Hurder A, et al. Assess- ment of letrozole and tamoxifen alone and in sequence forpostmenopausal women with steroid hormone receptor-posi- tive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up[ J ]. Lancet Oncol, 2011,12 (12) :1101-1108.
  • 8Safra T, Bernstein-Molho R, Greenberg J, et al. The pro- tective effect of zoledronic acid on bone loss in postmeno- pausal women with early breast cancer treated with se- quential tamoxifen and letrozole: a prospective, random- ized, phase II trial [ J ]. Oncology, 2011,81 ( 5-6 ) : 298- 305.
  • 9Gibson L, Lawrence D, Dawson C, et al. Aromatase in- hibitors for treatment of advanced breast cancer in postm- enopausal women[ J]. Cochrane Database Syst Rev, 2009, 7(4) : CD003370.
  • 10Obiorah I, Jordan V C. Progress in endocrine approaches to the treatment and prevention of breast cancer[ J]. Matu- ritas, 2011,70(4) :315-321.

引证文献1

;
使用帮助 返回顶部